 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
International News Anti-HIV Drug Set for Testing in ChinaApril 17, 2007 The state-run China Daily reported today that scientists there will soon begin testing Nifeviroc, China's first candidate entry-inhibitor HIV drug. Nifeviroc inhibits the CCR5 surface protein. "The CCR5 protein provides a medium through which [HIV] can infect healthy cells. By deactivating the protein, the virus can be stopped before it enters the cell," said Ma Dawei, a researcher with the Shanghai Institute of Organic Chemistry. In early tests, the orally administered drug had promising antiviral properties and few side effects, the report said. Scientists expect it would be three to five years before the drug could be put into clinical use. Agence France Presse 4.17.2007  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
